Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review
Sign Up to like & getrecommendations! Published in 2017 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620717699365
Abstract: With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease of the elderly. At this age, many patients cannot bear an intensive chemoimmunotherapy like fludarabine, cyclophosphamide and rituximab… read more here.
Keywords: cll; treatment; lymphocytic leukaemia; unfit patients ... See more keywords
A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01118
Abstract: PURPOSE The intended clinical value of frailty screening is to identify unfit patients needing geriatric assessment (GA) and to prevent unnecessary GA in fit patients. These hypotheses rely on the sensitivity and specificity of screening… read more here.
Keywords: curve analysis; unfit patients; analysis; decision curve ... See more keywords
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers14010207
Abstract: Simple Summary This prospective, multicenter study aimed to investigate the efficacy and safety of a front-line treatment with the ibrutinib and rituximab combination in 146 unfit patients with chronic lymphocytic leukemia (CLL). We observed an… read more here.
Keywords: rituximab combination; ibrutinib rituximab; treatment; unfit patients ... See more keywords